Aurinia Pharmaceuticals Inc (AUPH NASDAQ) stock market data APIs
$15.917
0.06(0.4%)
as of April 17, 2026
Try our APIs with
free plan!
Aurinia Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Prev. Close
15.917
Open
15.9803
High
16.2066
Low
15.8551
52 wk Range
7.285-16.54
Market Cap
2 134 M
P/E Ratio
7.7536
Shares Outstanding
133 M
Revenue
283 M
EPS
1.53
Beta
1.523
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aurinia Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aurinia Pharmaceuticals Inc data using free add-ons & libraries
Get Aurinia Pharmaceuticals Inc Fundamental Data
Aurinia Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 283 M
- EBITDA: 136 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-04
- EPS/Forecast: 0.1533
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aurinia Pharmaceuticals Inc News
New
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts across ther...
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California, March 30, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on deliveri...
Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up.
Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition. Continue Reading
Evommune Stock Sees RS Rating Rise To 91
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures mark...
Get Aurinia Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
